ArticleFrontiers in digital health2025
Enhancing neuropsychological assessment clinical pathways in Parkinson's disease through the use of technology.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.Age and ageing · 2026Guideline
- Barriers and enablers to cognitive assessment in Parkinson's disease: A qualitative contextual inquiry.Journal of Parkinson's disease · 2026Article
- Implementing Technology in Neuropsychological Assessments: A Scoping Review.Journal of medical systems · 2026Article
- What can we do to enhance cognitive care in Parkinson's disease?Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Routine administration of neuropsychological assessments to evaluate cognitive decline in Parkinson's disease (PD) may not be feasible in current clinical services. This is due to lengthy administration time, lack of specialised neuropsychologists and other limitations in resources. While technology integration could improve efficiency, understanding the existing assessment journey is crucial for successful implementation in clinical services. This preliminary study from the PDCogniCare project aims to explore current practice in neuropsychological assessments for people with PD and identify opportunities for technological integration. Methods: A qualitative study using semi-structured interviews was conducted with 15 clinical experts across two public health services in Australia. Data were analysed using inductive coding and journey mapping approaches to develop a comprehensive map of neuropsychological assessment journey. Results: Analysis revealed a four-phase assessment journey: initiation, brief cognitive screening, detailed neuropsychological assessment, and feedback, with distinct variations between clinical pathways. Key challenges included long waiting times, assessment duration, complex reporting, and limited awareness of cognitive assessments. While technology integration could begin to address some of these challenges through streamlined processes and improved access, barriers such as system integration, user adoption, and assessment methodology constraints require consideration. Conclusion: This study revealed the complexity of neuropsychological assessment pathways and identified potential areas for technological enhancement. Future research from the PDCogniCare project will aim to address these areas by employing appropriate methodologies and theoretical models to guide the design and development of technologies for neuropsychological assessments in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.